For clinics and prescribers
Ibogaine carries real cardiac risk, and most of that risk is managed before the dose is given. These pages set out how experienced programmes handle screening, monitoring, medication review, documentation and jurisdictional obligations — written for prescribers, medical directors and clinic managers rather than for patients.
What to establish before a dose is prescribed: ECG and QTc measurement, electrolytes, structural and rhythm history, family sudden-death history, and how a cleared, caution or contraindicated decision gets documented.
ReadStructured medication disclosure, substance-specific interaction screening, serotonin-related risk, and why any medication change belongs with the patient's own prescriber rather than the treatment programme.
ReadOral and IV ibogaine HCl, sublingual iboga total alkaloid, root bark, flood, titrated, booster and microdose — each with its own observation window, vitals interval and escalation triggers.
ReadWhat a psychedelic treatment programme needs from its record system: role-based access, server-side alerting, auditability, assessment scoring, adverse event registers and exportable clinical reports.
ReadThe regulatory shapes clinics operate under — prescription medicine, controlled substance, unscheduled, or research-only — and what each means for documentation, consent and oversight.
Read